Legend Biotech (LEGN) Non-Current Assets (2019 - 2025)
Legend Biotech (LEGN) posted Non-Current Assets of $486.6 million for Q4 2025, up 3.32% on a QoQ basis from $470.9 million in Q3 2025, and up 25.96% year-over-year from $386.3 million in Q4 2024.
Legend Biotech (LEGN) has 7 years of Non-Current Assets data on file, last reported at $486.6 million in Q4 2025.
- In Q4 2025, Non-Current Assets rose 25.96% year-over-year to $486.6 million; the TTM figure through Dec 2025 stood at $486.6 million (up 25.96% YoY), while the FY2025 annual figure was $486.6 million, up 25.96% from the prior year.
- Non-Current Assets advanced to $486.6 million in Q4 2025, from $470.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $486.6 million in Q4 2025 and bottomed at $140179.0 in Q1 2021.
- A 5-year average of $305.0 million and a median of $340.7 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 155006.86% — and 2025, when it rose 9.84%.
- Year by year, Non-Current Assets stood at $169.6 million in 2021, then soared by 36.69% to $231.8 million in 2022, then soared by 51.31% to $350.8 million in 2023, then advanced by 10.12% to $386.3 million in 2024, then grew by 25.96% to $486.6 million in 2025.
- The last three Non-Current Assets figures came in at $486.6 million (Q4 2025), $470.9 million (Q3 2025), and $440.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 285.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 486.60 Mn |
| Sep 30, 2025 | 470.94 Mn |
| Jun 30, 2025 | 440.04 Mn |
| Mar 31, 2025 | 396.86 Mn |
| Dec 31, 2024 | 386.30 Mn |
| Sep 30, 2024 | 385.79 Mn |
| Jun 30, 2024 | 373.35 Mn |
| Mar 31, 2024 | 361.32 Mn |
| Dec 31, 2023 | 350.81 Mn |
| Sep 30, 2023 | 330.54 Mn |
| Jun 30, 2023 | 317.80 Mn |
| Mar 31, 2023 | 293.96 Mn |
| Dec 31, 2022 | 231.84 Mn |
| Mar 31, 2022 | 179.78 Mn |
| Dec 31, 2021 | 169.62 Mn |
| Sep 30, 2021 | 160.40 Mn |
| Jun 30, 2021 | 154.29 Mn |
| Mar 31, 2021 | 140,179.00 |
| Dec 31, 2020 | 128.15 Mn |
| Sep 30, 2020 | 105,919.00 |
| Jun 30, 2020 | 99,474.00 |
| Dec 31, 2019 | 80.61 Mn |